StockData

Nektar Therapeutics vs Nkarta

NKTR and NKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NKTR and NKTX compare

Nektar Therapeutics is the larger company, worth 14 times as much as Nkarta ($1.2B against $89.5M).

Nektar Therapeutics scores higher on the StockData Score (9 against 7 for Nkarta), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNKTRNKTX
Size and price
Market cap$1.2B$89.5M
Share price$35.91$1.25
Change, 1 year−36.6%−33.2%
Change, 5 years−78.6%−92.3%
Beta (5Y)0.653.10
Employees63108
StockData Score
Total score9 (better)7
Valuation score11
Growth score1 (better)0
Performance score2 (better)1
Health score55
Dividend score00
Valuation
P/S22.2×–
P/B1.4×0.4× (better)
FCF yield−17.0% (better)−105%
Growth
Revenue growth (TTM)−43.9%–
Revenue growth, 5Y average−18.4%–
Profitability
Gross margin100%–
Operating margin−254%–
Net margin−297%–
FCF margin−378%–
Return on equity−37.3% (better)−38.8%
Return on invested capital−1186%−157% (better)
Financial health
Debt / equity0.000.00
Current ratio10.42 (better)7.98
Altman Z-score−0.72 (better)−3.08
Piotroski F-score33
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions105%82.9%
Held by insiders0.46%35.8%
Insider net buying, 12 months−$2.2M−$70.4K (better)
Short interest, % of float19.9%8.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.